

1 **Analysis of clinical characteristics of invasive**
2 **non-typhoidal *Salmonella* infections in children: a 5-year**
3 **dual-center retrospective study**

4 **Chenggang Lu¹, Yongping Xie¹, Yan Li¹, Fangfang Cheng², Lisu Huang¹, Wang**
5 **Hua^{1*}**

6 1 Department of Infectious Disease, Zhejiang University School of Medicine Children's
7 Hospital, National Clinical Research Center for Child Health, Hangzhou, Zhejiang, China

8 2 Department of Infectious Disease, Children's Hospital of Soochow University, Suzhou,
9 Jiangsu, China

10 *huawang01@126.com

11 **Abstract**

12 Objective: To investigate the incidence, microbiological characteristics, clinical
13 manifestations, and antibiotic resistance of invasive non-typhoidal *Salmonella* (iNTS)
14 infections in children.

15 Methods: A retrospective study was conducted from January 2018 to December 2022 at
16 two large teaching hospitals: Zhejiang University School of Medicine Children's Hospital
17 (ZCH) and Children's Hospital of Soochow University (SCH). Medical records of
18 culture-confirmed iNTS cases were reviewed, and a standardized case report form was
19 used to collect demographic, clinical, and microbiological data.

20 Results: A total of 109 cases of iNTS infection were included, with 40 cases from SCH
21 and 69 cases from ZCH. 71 cases (65.1%) were boys.. Infants under 1 year old accounted

22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
for 50.9% of the cases. Among the cases, 38 cases (34.9%) had underlying diseases;

23 mainly tumors (55.3%,21/38). The most common sites of infection were the bloodstream
24 (84.4%) and bones and joints (12.8%). The most common serogroups were B (36.8%) ,C
25 (44.7%) and D (38.2%). The overall resistance rate of ampicillin was 53.6%, ceftriaxone
26 resistance rate was 17.8%, and carbapenem resistance rate was 0%. Seasonal trends
27 indicated higher incidence rates during the summer.

28 Conclusion: iNTS infections in children primarily affect the bloodstream and
29 bones/joints, with a significant proportion of cases in those with underlying medical
30 conditions. Ceftriaxone remains the first-line antibiotic, but increasing resistance highlights
31 the need for vigilant antimicrobial stewardship. Carbapenems can be considered as
32 second-line antibiotics in severe cases. Further studies are needed to understand the
33 molecular characteristics and improve treatment strategies for iNTS infections in pediatric
34 patients.

35 Introduction

36 *Salmonella* is easily transmitted to the human body through foodborne and direct
37 contact routes, and it is a common pathogen in pediatric gastrointestinal infections. Some
38 cases present with extraintestinal infections, including bacteremia and secondary focal
39 lesions. A systematic review estimated(1)that in 2017, there were 535,000 cases of
40 invasive non-typhoidal *salmonella* (NTS) disease globally, resulting in 77,500 deaths.
41 Megged et. al report that the age characteristics of NTS bloodstream infection show a
42 U-shaped distribution and were more common in children and the elderly(2). The highest
43 incidence rate of invasive non-typhoidal *salmonella* disease was observed in children
44 under the age of 5, reaching 34.3 per 100,000 person-years(1). According to a systematic

45 review and analysis of literature on NTS invasive disease cases before June 2021, the
46 overall pooled case-fatality ratio estimates were as follows: 14.7% in Africa, 14.0% in Asia,
47 9.6% in the Americas, and 9.9% in Europe(3). Data from the provinces of Zhejiang and
48 Henan in China indicate that 20.9% to 43.6% of NTS cases result in invasive infections,
49 with 52.8% to 67.9% of these cases being bloodstream infections. Furthermore, more
50 than half of the cases affected children(4). Bloodstream infections without appropriate
51 antibiotic treatment are fatal, and changes in antibiotic resistance spectrum can lead to
52 treatment failure and dissemination of infection. To date, there is a lack of comprehensive
53 and in-depth understanding among pediatric clinicians regarding invasive salmonella
54 infections, becoming a clinically significant issue that cannot be ignored.

55 **Materials and Methods**

56 **Study Population and Data Collection**

57 The study included all subtypes of NTS except for typhoid and paratyphoid strains.
58 Invasive non-typhoidal *Salmonella* infections (iNTS) were defined as cases where
59 specimens cultured from any normally sterile site were positive. The serogroup of the
60 *Salmonella* isolates was determined using slide agglutination with antisera, and the
61 isolates were classified into seven serogroups: serogroup A-E and other serogroups.
62 Antimicrobial susceptibility testing was determined using a commercial microdilution
63 method (VITEK COMPACT, BioMerieux, France), and the results were interpreted
64 according to Clinical Laboratory Standards Institute guideline M100-ED32. Susceptibility
65 to ampicillin, ceftriaxone, chloramphenicol, imipenem, ciprofloxacin, and
66 trimethoprim/sulfamethoxazole (SMZ) was tested. *E. coli* ATCC25922 was used for quality

67 control. A retrospective analysis was conducted on iNTS data from the Zhejiang University
68 School of Medicine Children's Hospital (ZCH) and the Children's Hospital of Soochow
69 University (SCH) from January 2018 to December 2022. Medical records of confirmed
70 cases were retrieved, and a standardized case report form was used to collect information
71 on age, gender, underlying medical history, symptoms, laboratory examinations, and
72 antimicrobial susceptibility. The pediatric sequential organ failure assessment (pSOFA)
73 score was evaluated according to the previous literature(5). Meteorological data were
74 obtained from the Zhejiang Government Services Network (www.zjzfw.gov.cn) and
75 JiangSu Meteorological Administration (js.cma.gov.cn).

76 **Statistical Analysis**

77 Non-normal variables were presented as median and interquartile range; and
78 categorical variables were described as frequencies. Differences in continuous variables
79 between the bloodstream infection (BSI) group and non-BSI group, as well as between
80 the age >1 year group and the age ≤ 1 year group, were compared using the
81 nonparametric Mann-Whitney U test. Proportions were compared using the χ -squared
82 test. $P < 0.05$ was considered statistically significant. All statistical analyses were
83 performed using SPSS statistical 27.0 software (IBM, Armonk, NY, USA).

84 **Ethics statement**

85 The study was approved by Medical Ethics Committee of the Zhejiang University
86 School of Medicine Children's Hospital and the Children's Hospital of Soochow University
87 (2024-IRB-0193-P-01). Written assent forms were obtained from all participants, along
88 with written consent forms from their guardians.

89 **Results**

90 109 cases of iNTS infection were included in the study, with 40 cases from SCH and 69
91 cases from ZCH. Of these, 71 cases (65.1%) were boys. Additionally, there were 33
92 infants (30.3%) under one year old. 38 cases (34.9%) had underlying diseases, mainly
93 tumors (21 cases), including 19 cases of acute leukemia, 1 case of bone tumor, and 1
94 case of optic nerve neuroepithelial tumor. None of the cases were co-infected with HIV.
95 There were 92 cases (84.4%) of bloodstream infection, 7 cases of bone marrow infection,
96 7 cases of joint infection, 2 cases of central nervous system infection, and 1 case of
97 pleural effusion. The median time to positive blood culture was 15.8 hours, and the
98 median length of hospital stay was 12 days. There were three deaths, all from ZCH, two of
99 which were boys with acute lymphoblastic leukemia and *Salmonella* group D infection,
100 and one was a girl with acute monocytic leukemia and *Salmonella* group B infection. They
101 had significantly elevated pSOFA scores. All three cases had decreased platelet counts
102 and significantly elevated CRP levels.

103 In terms of monthly case numbers and temperature, the curve trends suggest a clear
104 correlation between temperature and the number of cases in both children's hospitals,
105 which increasing markedly in summer when temperatures are high. while the correlation
106 with relative humidity is not obvious. (Fig.1)




Fig. 1 Relationship between monthly distribution of iNTS infections and temperature and humidity

107

108 Compared to the BSI group, the non-BSI group had a significantly higher incidence of
 109 bone and joint symptoms (52.9% vs. 4.3%, $P < 0.001$), higher white blood cell
 110 count [$7.9 \times 10^9/L$ vs. $11.1 \times 10^9/L$, $P=0.009$], higher platelet count [$226.5 \times 10^9/L$ vs.
 111 $414.0 \times 10^9/L$, $P < 0.001$], and longer duration of effective antibiotic use (9.0days vs.
 112 25.0days, $P < 0.001$). There were no significant differences in other indicators. (Tables 1)

113 Compared to children over 1 year old, infants aged 1 year or less with iNTS infection
 114 had a higher proportion of serogroups B strains (42.4% vs. 18.4%, $P = 0.008$), a lower
 115 proportion of serogroups D strains (12.1% vs. 32.9%, $P = 0.024$), a higher prevalence of
 116 gastrointestinal symptoms (57.6% vs. 26.3%, $P = 0.002$), a lower proportion of
 117 hematological system involvement (0% vs. 25.0%, $P = 0.002$), a lower proportion of
 118 underlying diseases (21.2% vs. 40.8%, $P = 0.049$), a lower proportion of tumor (0% vs.
 119 27.6%, $P = 0.001$), a lower proportion of deep venous catheterization (3.0% vs. 30.3%, P
 120 = 0.002). There were no significant differences in other parameters. (Tables 1)

Table 1. Demographic and clinical manifestations of children with iNTS infections, 2018–2022.

Variables	n	BSI	n	Non-BSI iNTS	χ^2/Z	<i>P</i>	n	Age >1 year	n	Age ≤ 1 year	χ^2/Z	<i>P</i>
Demographic												
Boys, n (%)	92	59(64.1)	17	12(70.6)	0.264	0.608	76	50(65.8)	33	21(63.6)	0.047	0.828
Age, months, median (IQR)	92	19.5(12.0,56.3)	17	17.0(10.1,23.0)	-1.374	0.169	/	/	/	/	/	/
Underlying diseases, n (%)	92	34(37.0)	17	4(23.5)	1.139	0.286	76	31(40.8)	33	7(21.2)	3.883	0.049
Tumors, n (%)	92	20(21.7)	17	1(5.9)	1.412	0.235	76	21(27.6)	33	0(0)	11.294	0.001
Deep vein catheter, n (%)	92	23(25.0)	17	1(5.9)	2.042	0.153	76	23(30.3)	33	1(3.0)	9.938	0.002
Laboratory examinations												
WBC, × 10 ⁹ /L, median (IQR)	92	7.9(4.3,11.7)	17	11.1(8.9,13.9)	-2.622	0.009	76	7.6(3.8,11.1)	33	10.4(7.5,15.2)	-3.242	0.001
CRP, mg/L, median (IQR)	92	17.4(5.8,34.3)	17	11.5(4.4,56.3)	-0.167	0.867	76	13.1(2.5,32.6)	33	22.6(7.3,45.2)	-1.636	0.102
PCT, ng/mL, median (IQR)	73	0.3(0.2,0.5)	9	0.2(0.1,10.5)	-0.334	0.739	60	0.3(0.2,0.5)	22	0.4(0.2,0.8)	-1.136	0.256
Plt, × 10 ⁹ /L, median (IQR)	92	226.5(109.0,306.0)	17	414.0(266.0,565.5)	-4.021	< 0.001	76	212.5(64.0,298.3)	33	311.0(253.5,380.5)	-4.327	< 0.001
ALT, U/L, median (IQR)	92	30.0(16.3,62.6)	17	23.0(15.0,34.5)	-1.282	0.200	76	26.2(16.0,55.8)	33	27.0(19.6,57.2)	-0.571	0.568
AST, U/L, median (IQR)	92	48.2(36.0,81.1)	17	38.0(30.5,52.5)	-1.716	0.086	76	47.0(33.2,69.8)	33	48.6(36.0,92.4)	-0.966	0.334
Total bilirubin, umol/L, median (IQR)	91	5.4(3.6,10.5)	16	5.1(3.7,8.3)	-0.135	0.892	74	5.7(4.0,10.7)	33	4.1(3.0,6.8)	-1.886	0.059
Serum creatinine, umol/L, median (IQR)	92	27.5(21.0,39.5)	17	24.0(17.0,36.0)	-1.090	0.276	76	29.0(21.0,37.7)	33	23.6(20.2,39.5)	-1.029	0.303
Blood lactate, mmol/L, median (IQR)	91	2.2(1.7,2.9)	17	2.0(1.5,2.5)	-0.959	0.338	75	2.1(1.7,2.9)	33	2.4(1.7,3.0)	-0.478	0.633
Serogroup, n (%)												
B		24(26.1)		4(24.5)	0.000	1.000		14(18.4)		14(42.4)	6.945	0.008
C	92	26(28.3)	17	8(47.1)	2.362	0.124	76	25(32.9)	33	9(27.3)	0.339	0.560
D		27(29.3)		2(11.8)	1.461	0.227		25(32.9)		4(12.1)	5.085	0.024

E		8(8.7)		0(0)	0.573	0.449		5(6.6)		3(9.1)	0.004	0.950
non A-E		7(7.6)		3(17.6)	0.740	0.390		7(9.2)		3(9.1)	0.000	1.000
Source of infection												
BSI, n (%)	/	/	/	/	/	/		66		26	1.134	0.287
Non-BSI, n (%)	/	/	/	/	/	/		10		7		
Clinical presentations, n (%)												
Fever		69(75.0)		10(58.8)	1.882	0.170		52(68.4)		27(81.8)	2.070	0.150
Gastrointestinal symptoms		35(38.0)		4(23.5)	1.315	0.251		20(26.3)		19(57.6)	9.785	0.002
Cough		7(7.6)		2(11.8)	0.327	0.567		6(7.9)		3(9.1)	0.043	0.835
Hematological symptoms	92	18(19.6)	17	1(5.9)	1.866	0.172	76	19(25.0)	33	0(0)	9.992	0.002
Bone and joint		4(4.3)		9(52.9)	32.255	< 0.001		10(13.2)		3(9.1)	0.362	0.547
Others		7(7.6)		2(11.8)	0.009	0.926		6(7.9)		3(9.1)	0.000	1.000
pSOFA≥2, n (%)	92	50(54.3)	17	5(29.4)	3.569	0.059	76	34(44.7)	33	20(60.6)	2.318	0.128
Outcomes												
Duration of effective antibiotic use, days, median (IQR)	92	9.0(7.0,12.0)	17	25.0(11.5,42.0)	-4.091	< 0.001	76	10.0(7.0,13.8)	33	9.0(6.5,13.0)	-0.754	0.451
Length of hospital stay, days, median (IQR)	92	12.0(9.0,17.8)	17	17.0(10.0,53.0)	-1.945	0.052	76	12.0(9.0,26.5)	33	13.0(8.5,17.0)	-0.423	0.672
Time to positive blood culture, hours, median (IQR)	92	15.8(13.0,21.2)	17	16.8(8.4,46.5)	-0.359	0.719	76	15.7(12.6,21.3)	33	16.4(12.3,25.9)	-0.155	0.877
Death, n (%)	92	3(3.3)	17	0(0)	0.570	0.450	76	3(3.9)	33	0(0)	1.339	0.247

122 In the strain serogroups, there were 28 cases (36.8%) in serogroup B, 34 cases (44.7%)
 123 in serogroup C, 29 cases (38.2%) in serogroup D, 8 cases in serogroup E, and 10 cases
 124 in non-A-E serogroup. The overall resistance rate of ampicillin was 53.6% (45/84),
 125 ceftriaxone resistance rate was 17.8% (19/107), SMZ resistance rate was 27.1% (29/107),
 126 ciprofloxacin insensitivity rate was 35.3% (30/85), chloramphenicol resistance rate was
 127 35.6% (16/45), and carbapenem resistance rate was 0%. There were significant
 128 differences in the resistance of ampicillin, ceftriaxone, SMZ, and chloramphenicol among
 129 different NTS serogroups, while there was no significant difference in ciprofloxacin
 130 insensitivity rate. (Table 2)

Table 2. Antibiotic resistance of different Serogroups of NTS to six antibiotics

Antibiotic	Serogroup B	Serogroup C	Serogroup D	Serogroup E	Serogroup non A-E	χ^2	P
Ampicillin	12/21(57.1%)	9/29(31.0%)	19/25(76.0%)	3/3(100%)	2/6(33.3%)	16.222	0.003
Ceftriaxone	8/28(28.6%)	2/33(6.1%)	4/28(14.3%)	5/8(62.5%)	0/10(0%)	17.941	0.001
SMZ	15/28(53.6%)	6/33(18.2%)	2/28(7.1%)	5/8(62.5%)	1/10(10.0%)	23.573	<0.001
Ciprofloxacin	11/21(52.4%)	7/29(24.1%)	9/26(34.6%)	1/3(33.3%)	2/6(33.3%)	4.254	0.373
Chloramphenicol	9/11(81.8%)	4/16(25.0%)	2/15(13.3%)	1/1(100%)	0/2(0%)	18.368	0.001
Carbapenems	0/20(0%)	0/17(0%)	0/17(0%)	0/8(0%)	0/7(0%)	/	/

131 Discussion

132 Among the 109 cases of iNTS, nearly 2/3 (65.1%) were boys, 38 cases had underlying
 133 diseases, and nearly half had acute lymphoblastic leukemia. The three death cases all
 134 came from bloodstream infection in children with hematological tumors after
 135 chemotherapy. The pSOFA score increased significantly. Due to the small number of
 136 death cases, statistical analysis of high-risk factors cannot be performed. pSOFA is helpful
 137 for disease assessment and prognosis judgment. It should be mentioned that the pSOFA

138 score indicators include serum creatinine and bilirubin, which limits early clinical
139 application(5). Different from the total case fatality rate estimated in global reviews of
140 14.7%(3). there were few deaths in this study. Considering the different underlying
141 disease spectrum, there were no children with HIV, which may also be the reason for the
142 large difference in mortality. We noticed that there were no fatal cases reported in NTS
143 bloodstream infection studies from Malaysia(6), Israel(2), Japan(7), and Taiwan, China(8).

144 The incidence of iNTS in children in both centers is related to temperature. During the
145 high temperature season in summer, the number of incidences reaches a peak, while in
146 winter and spring, the number of incidences decreases significantly. Possible factors
147 include rising temperatures, easy reproduction of bacteria, easy deterioration of food, and
148 water pollution, which are all risk factors for increasing NTS infection. Mohan et al. from
149 Malaysia reported that there was no significant correlation between the monthly incidence
150 of iNTS and the average monthly rainfall(9). In Hong Kong, China, it was reported that the
151 peak of hospitalization for NTS infection was in June and the trough was in April(10). It
152 shows that different latitudes in different regions are related to the seasonal
153 characteristics of NTS incidence.

154 In this group of studies, the most common were BSI (84.4%) and bone and joint
155 infection (12.8%). The clinical characteristics of the two groups and the antibiotic
156 resistance are basically similar. The non-BSI iNTS group has a younger age of onset and
157 longer antibiotic treatment time, suggesting that the non-BSI iNTS may have experienced
158 a BSI process. Infections caused by blood circulation dissemination, it will take longer to
159 clear the germs that spread the lesions. The higher white blood cell and platelet counts in

160 the non-BSI group suggest a more severe inflammatory response in cases of non-BSI.
161 Clinically, joint infection may spread hematogenously or directly spread from open wounds.
162 This data found that the clinical parameters of the BSI group and the non-BSI iNTS group
163 were mostly the same, and the clinical characteristics were similar, suggesting that the
164 invasive infection group without BSI had bloodstream infection in early stage and spread
165 the lesions through the blood circulation. The antibiotic treatment time in the non-BSI iNTS
166 group was 2.5 times longer, indicating that it takes longer to clear bacteria from bone
167 marrow, joints, cerebrospinal fluid and other lesions. Two studies in the United States
168 compared the duration of intravenous antibiotic treatment for NTS BSI in children with >3
169 days to ≤ 3 days(11), and compared the duration of <7 days with ≥ 7 days(12). The clinical
170 outcomes were good, and recommendations with oral antibiotics can be made as soon as
171 possible. However, these two groups of cases were mild children with no invasive
172 infection lesions and no underlying diseases, which were different from the cases studied
173 in our groups.

174 Comparing the age groups, it can be found that serogroup B is more common in the
175 infant group and serogroup D is less common. Clinical symptoms such as diarrhea and
176 vomiting are more common. The proportion of older children with underlying diseases
177 (mainly leukemia) and deep vein catheterization is higher than that of infants, indicating
178 that with the age increases, acquired immune function strengthens, and the number of
179 iNTS infections among children with normal immune function gradually decreases. The
180 study by Sirinavin et al. from Thailand reported a group of 75 infant iNTS cases, including
181 transient bacteremia (5), bacteremia without localized infection (37), bone and joint

182 infection (5) and meningitis (28); while in our two centers, the cases were primarily
183 bloodstream infections, only 2 cases of central nervous system infection, indicating a
184 different spectrum of the disease. This also highlights the importance for clinicians to be
185 vigilant about intracranial infections in infant iNTS infections(13).

186 NTS from different specimen sources are similar in antibiotic resistance, suggesting that
187 infections at other invasion sites may also be caused by dissemination of BSI. In this study,
188 the serogroups were predominantly B, C, and D, with relatively few serogroups E and
189 other groups, which is similar to what was reported by Megged et al(2). In the NTS BSI
190 reported by Lee et al. in Taiwan, serogroup D was the most common(14), their study
191 showed that the ampicillin resistance rate was 53%, the third-generation cephalosporin
192 resistance rate gradually increased to 11%, and the ciprofloxacin resistance rate dropped
193 from 20% to 11%. In this study, ampicillin resistance exceeded 50%, carbapenem
194 resistance was 0%, SMZ resistance was 27%, ceftriaxone resistance was 18%, and
195 ciprofloxacin was mostly intermediate, with a proportion close to 35%. Our data indicate
196 the emergence of extensive resistance to ampicillin, suggesting that Salmonella has
197 extensively produced β -lactamase. Most are sensitive to ceftriaxone, but the resistance
198 rate continues to rise. Some studies have used pulsed field gel electrophoresis to identify
199 Salmonella strains that are resistant to ceftriaxone and identified the blaCMY-2 gene on
200 the Inc11 plasmid; through horizontal gene transfer, the MIC of ceftriaxone for the recipient
201 strain increased from 0.125 μ g/mL to 32 μ g/mL(15). The ciprofloxacin resistance rate has
202 not declined because there are more intermediaries, which is closely related to the
203 breakpoints defined by the Clinical Laboratory Standards Institute guidelines. Comparing

204 the antibiotic resistance of different serogroups, it was found that serogroup E had the
205 highest resistance rate to ampicillin, ceftriaxone, SMZ, and chloramphenicol. The
206 resistance rate of ceftriaxone in serogroup C was 6.1%, while the resistance rate in
207 serogroup E was the highest at 62.5%. To date, Ceftriaxone is still the first-line drug and
208 serogroups has a certain guiding role in the selection of antibiotics. It is noteworthy that
209 the drug resistance rate of Salmonella is gradually increasing. Garcia et al. in Peru
210 reported multidrug-resistant Salmonella serovar Infantis (from serogroup C) were only
211 sensitive to carbapenems(16). In our study, all carbapenems are sensitive. Considering
212 that children with iNTS are more likely to have underlying diseases and have immune
213 dysfunction, carbapenem antibiotics can be used as second-line antibiotics when severe
214 invasive infections occur.

215 This study is a retrospective study, and the strains isolated from the specimens are only
216 grouped into serogroups without serotype classification, which limits further analysis of
217 molecular characteristics. Secondly, the specimens of invasive infection are mainly from
218 blood, bone and joint, and there is very little from CSF and pleural effusion, which limits
219 in-depth comparative analysis of clinical characteristics. However, the 109 iNTS cases are
220 still a relatively large cohort and can provide meaningful reference for subsequent
221 research on the clinical characteristics and treatment of Salmonella.

222 Conclusion: The clinical manifestations and treatment of iNTS infection in children are
223 related to the site of invasion. Ceftriaxone is still the first-line antibiotic, but the resistance
224 is gradually increasing. Carbapenems can be considered as second-line antibiotics in
225 severe cases.

226

227

References:

- 228 1. Stanaway JD, Parisi A, Sarkar K, Blacker BF, Reiner RC, Hay SI, et al. The global burden of
229 non-typhoidal salmonella invasive disease : a systematic analysis for the Global Burden of Disease
230 Study 2017. *LANCET INFECT DIS*. 2019 2019/1/1;19(12):1312-24.
- 231 2. Megged O, Assous M. Non-typhoidal Salmonella bacteremia : comparison of adults and children
232 in a single medical center. *J MED MICROBIOL*. 2022 2022/1/1;71(5).
- 233 3. Marchello CS, Birkhold M, Crump JA. Complications and mortality of non-typhoidal salmonella
234 invasive disease: a global systematic review and meta-analysis. *LANCET INFECT DIS*. [Journal
235 Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't;
236 Systematic Review]. 2022 2022/5/1;22(5):692-705.
- 237 4. Hu Y, Wang J, Chen S, Li Y, Zhang R, Chen S. Non-typhoidal salmonella invasive infections in
238 China. *LANCET INFECT DIS*. [Comment; Letter; Research Support, Non-U.S. Gov't]. 2022
239 2022/7/1;22(7):939.
- 240 5. Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure
241 Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. *JAMA*
242 *PEDIATR*. [Journal Article; Observational Study; Validation Study]. 2017 2017/10/2;171(10):e172352.
- 243 6. Nor AA, Fadzilah MN, Mariam M, Anis SZ, Ariza A, Noor SM, et al. Community-acquired
244 bacteremia in Paediatrics: Epidemiology, aetiology and patterns of antimicrobial resistance in a
245 tertiary care centre, Malaysia. *Med J Malaysia*. [Journal Article]. 2016 2016/6/1;71(3):117-21.
- 246 7. Aoki Y, Kitazawa K, Kobayashi H, Senda M, Arahata Y, Homma R, et al. Clinical features of
247 children with nontyphoidal Salmonella bacteremia: A single institution survey in rural Japan. *PLOS*
248 *ONE*. [Journal Article]. 2017 2017/1/20;12(6):e176990.
- 249 8. Chang Y, Chen Y, Chen N, Hsu Y, Chu H, Chen C, et al. Changing Antimicrobial Resistance and
250 Epidemiology of Non-Typhoidal Salmonella Infection in Taiwanese Children. *FRONT MICROBIOL*.
251 2021;12.
- 252 9. Mohan A, Munusamy C, Tan Y, Muthuvelu S, Hashim R, Chien S, et al. Invasive Salmonella
253 infections among children in Bintulu , Sarawak , Malaysian Borneo : a 6-year retrospective review.
254 *BMC INFECT DIS*. 2019;19.
- 255 10. Woh PY, Yeung MPS, Nelson EAS, Goggins WBI. Risk factors of non-typhoidal Salmonella
256 gastroenteritis in hospitalised young children : a case-control study. *BMJ PAEDIATR OPEN*. 2021
257 2021/1/1;5(1).
- 258 11. Glover B, Charvat C, Weiss L, Kirpalani A, Shane AL, Li R, et al. Intravenous Antibiotic Duration
259 for Nontyphoidal Salmonella Bacteremia in Children. *Hosp Pediatr*. [Journal Article]. 2022
260 2022/7/1;12(7):e225-9.
- 261 12. Hess LM, Burdick B, Minard CG, Dutta A. IV Antibiotic Durations for Nontyphoidal Salmonella
262 Bacteremia. *Hosp Pediatr*. [Journal Article; Observational Study]. 2019 2019/12/1;9(12):993-7.
- 263 13. Sirinavin S, Chiemchanya S, Vorachit M. Systemic nontyphoidal Salmonella infection in normal
264 infants in Thailand. *PEDIATR INFECT DIS J*. [Journal Article]. 2001 2001/6/1;20(6):581-7.
- 265 14. Lee CM, Lee MS, Yang TL, Lee KL, Yen TY, Lu CY, et al. Clinical features and risk factors
266 associated with bacteremia of nontyphoidal salmonellosis in pediatric patients, 2010-2018. *J*
267 *FORMOS MED ASSOC*. [Journal Article]. 2021 2021/1/1;120(1 Pt 1):196-203.

- 268 15. Yang WC, Chan OW, Wu TL, Chen CL, Su LH, Chiu CH. Development of ceftriaxone resistance
269 in *Salmonella enterica* serotype Oranienburg during therapy for bacteremia. J MICROBIOL
270 IMMUNOL. [Case Reports; Journal Article; Research Support, Non-U.S. Gov't]. 2016
271 2016/2/1;49(1):41-5.
- 272 16. Garcia C, Hinojosa N, Astocondor L, Ochoa T, Jacobs J, For TSCN. Characterization of
273 ESBL-Producing *Salmonella enterica* Serovar Infantis Infection in Humans, Lima, Peru. AM J TROP
274 MED HYG. [Journal Article; Research Support, Non-U.S. Gov't]. 2019 2019/10/1;101(4):746-8.
- 275